The BWX Technologies story
What drives BWX Technologies, what its price assumes and what could change the story, written from its own filings.
- Nuclear focus sharpens. BWXT announced the sale of its medical business and completed the Precision Components Group acquisition to establish a U.S. commercial nuclear manufacturing footprint.
- Commercial growth leads. Commercial Operations revenue rose 72% from a year earlier to $302.5 million in the quarter to June 2026, supported by nuclear components, services and Kinectrics.
- Cash trails revenue. Revenue reached $901.6 million in the quarter to June 2026, but free cash flow declined to $115.0 million from $126.3 million a year earlier as capital spending increased and tax payment timing affected operating cash.
